Max Weight Loss20.9%
Studies12
Participants8,750
StatusAvailable
Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Complete Research Database
Clinical Efficacy by Dose
3.1%
Placebo
7.6%
5 mg
15.7%
10 mg
20.9%
15 mg
Placebo
3.1%
5 mg
7.6%
10 mg
15.7%
15 mg
20.9%
Source: Clinical research data
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.